NEWS
Ikena Oncology Announces Strategic Update
Ikena Oncology announced they are discontinuing the development of IK-930, their TEAD1-selective Hippo pathway inhibitor. The company will continue the clinical development of IK-595, a MEK-RAF molecular glue showing promising PK and PD data in RAS and RAF mutant cancers. Ikena ended Q1 with $157.3 million in cash and is projecting $110-$120 million by year-end 2024. The company is exploring strategic options, including partnerships, mergers, or asset sales. A workforce reduction of approximately 53% will occur in connection with the discontinuation of IK-930.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2734Followers
108Following
29KVisitors
Follow